Design, synthesis, and preliminary activity evaluation of novel peptidomimetics as aminopeptidase N/CD13 inhibitors

Arch Pharm (Weinheim). 2011 Aug;344(8):494-504. doi: 10.1002/ardp.201100109. Epub 2011 Jun 16.

Abstract

The synthesis of a series of novel N-α-galloylated isoglutamic acid γ-amide peptidomimetics is described. Their enzymatic inhibition against aminopeptidase N (APN/CD13) and matrix metalloproteinase-2 (MMP-2) was tested. The preliminary activity assay revealed that most of the compounds displayed selective inhibition against APN as compared with MMP-2, with IC(50) values in a micromolar range. Within this series, compound 4 (IC(50) = 10.2 ± 0.9 µM) demonstrated comparable APN inhibition as compared with the positive control bestatin (IC(50) = 13.1 ± 0.7 µM), which might be a promising lead for further molecular optimizations.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD13 Antigens / antagonists & inhibitors*
  • CD13 Antigens / metabolism
  • Drug Design*
  • Inhibitory Concentration 50
  • Models, Molecular
  • Peptidomimetics / analysis
  • Peptidomimetics / chemical synthesis*
  • Peptidomimetics / metabolism
  • Structure-Activity Relationship

Substances

  • Peptidomimetics
  • CD13 Antigens